Rudy Willebrords
Overview
Explore the profile of Rudy Willebrords including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roymans D, De Bondt H, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, et al.
Proc Natl Acad Sci U S A
. 2009 Dec;
107(1):308-13.
PMID: 19966279
Six-helix bundle (6HB) formation is an essential step for many viruses that rely on a class I fusion protein to enter a target cell and initiate replication. Because the binding...
2.
Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, et al.
J Biol Chem
. 2008 Jul;
283(37):25273-25280.
PMID: 18625705
An estimated one-third of the world population is latently infected with Mycobacterium tuberculosis. These nonreplicating, dormant bacilli are tolerant to conventional anti-tuberculosis drugs, such as isoniazid. We recently identified diarylquinoline...
3.
Bonfanti J, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, et al.
J Med Chem
. 2008 Feb;
51(4):875-96.
PMID: 18254606
A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications...
4.
Bonfanti J, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P, et al.
J Med Chem
. 2007 Aug;
50(19):4572-84.
PMID: 17722899
We previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus (Andries, K.; et al. Antiviral Res. 2003, 60, 209-219). A lead compound of...
5.
Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al.
Nat Chem Biol
. 2007 May;
3(6):323-4.
PMID: 17496888
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not...
6.
Andries K, Moeremans M, Gevers T, Willebrords R, Sommen C, Lacrampe J, et al.
Antiviral Res
. 2003 Nov;
60(3):209-19.
PMID: 14638397
A cell-based assay was used to discover compounds inhibiting respiratory syncytial virus (RSV)-induced fusion in HeLa/M cells. A lead compound was identified and subsequent synthesis of >300 analogues led to...